A method of treating neuroinflammation in a subject, the method including administering to a subject a therapy for modulating a valeric acid-interleukin (IL)-17 pathway in the subject so that neuroinflammation in the subject is treated. The therapy administered to the subject can include exercise, fecal transplantation, an agent to decrease bacteria producing valeric acid, an agent for reducing IL-17, and/or an agent for reducing FFAR2, C3ar1, C3, Iba-1, IL-1β, and/or IL-6. Such agents can include RNA interference constructs and/or antibodies. Also provided are methods for improving neurological outcome and/or mediating inflammatory response in a subject suffering from ischemic stroke and/or surgery-induced neuroinflammation.
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Provided are tetravalent bispecific antibodies (T-BiAbs) that have a first binding moiety and a second binding moiety, wherein the first binding moiety is a single chain variable fragment (scFv) and the second, binding moiety-7 is a monoclonal antibody, and further wherein the variable light (Vi.) and variable heavy7 (VH) chains of the first binding moiety7 are directly linked as a. single chain to the second binding moiety at the N-terminus or the C-terminus of the light chain or the heavy chain sequence of the second binding moiety. In some embodiments, the first binding moiety binds to a CDS polypeptide and the second binding moiety-7 binds to a tumor-associated antigen. Also provided are T cells armed with the presently disclosed T-BiAbs and methods of using the same for treating tumor and/or cancers, treating diabetes, arming and isolating stem cells, and manufacturing medicaments for these purposes.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
3.
METAL OXIDE COMPOSITE STRUCTURES, METHODS OF MAKING THE STRUCTURES, AND SYSTEMS COMPRISING THE STRUCTURES
C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
5.
AUTOMATED CELL CULTURING AND CHARACTERIZATION TO RESEMBLE IN VIVO CONDITIONS
A method of automated cell culturing and characterization can include regulating one or more parameters of an ambient environment within an environmentally isolated, airtight enclosure. A biological specimen can be cultured within the enclosure, e.g., including aspirating and dispensing, via an automated fluid handling system having a fluidic interface disposed within the airtight enclosure, a portion of the biological specimen. The dispensing can be into a first vessel, e.g., by suspending individual cells of the portion of the biological specimen within a microcarrier matrix contained by the first vessel and exposed to the ambient environment within the airtight enclosure.
Disclosed herein are processes term Bacterial Chloro-Alkane Penetration Assay (BaCAPA) and Bacterial Azide Permeability Assay (BAPA) The processes employ a genetically encoded protein called HaloTag to measure the uptake and accumulation of molecules into Gram-negative bacteria. The processes aqre useful in assessing the permeation of molecules within the phagocytes of macrophages, and they effectively report on the accumulation of molecules into bacterial cells, thereby identifying potential antibiotic drugs.
A microfluidic system can be used to quantify apoptotic bodies (ABs) with single-cell sensitivity, providing real-time information regarding the presence, and properties of ABs. Different subpopulations of ABs can thus be distinguished from one another to quantify cellular dis-assembly and drug sensitivity of the cancer cells under test. Impedance measurement can be performed by flowing secreted bodies at a substantially single-particle sensitivity. A plurality of electrical impedance magnitude and phase parameters of the biological sample can be measured within the flow cell structure, corresponding to a specified range of frequencies to help determine a biological characteristic of the cancer cells.
Provided are compositions that include a histone deacetylase inhibitor (HDACi) encapsulated in and/or otherwise associated with a nanoparticle. In some embodiments, the HDACi is romidepsin, vorinostat, belinostat, panobinostat, and/or chidamide. In some embodiments, the nanoparticle is a poly(D,L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders, and/or conditions associated with sensitivity to histone deacetylase inhibitors, such as but not limited to tumors and/or cancers; and methods for inhibiting the growth, proliferation, and/or metastasis of a tumor and/or a cancer associated with sensitivity to histone deacetylase inhibitors by administering an effective amount of a composition as disclosed herein, which methods can optionally include administering at least one additional therapeutically active agent, such as but not limited to a chemotherapeutic agent.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCTION (USA)
UNIVERSITY OF VIRGINIA PATENT FOUNDATION (USA)
Inventor
Turnquist, Heth
Warunek, Jordan John Peter
Borrelli, Matthew Andrew
Balmert, Stephen C.
Little, Steven R.
Sharma, Rahul
Abstract
The presently disclosed subject matter relates to methods for selectively attracting cells to a target site in a subject, and methods for treating an inflammatory disease, an autoimmune disease, a malignancy, an infection, or a site of inflammation in a subject in need thereof. Specifically, the disclosed subject matter involves administering to the subject a composition comprising a sustained release microparticle comprising a CCL22 polypeptide, and/or cells expressing a CCR4 polypeptide. The present disclosure further relates to sustained release microparticles comprising a CCL22 polypeptide.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Provided are methods for identifying subjects at risk for reduced lifespan, age-associated cardiomyopathy, reduced cardiac function, heart failure, increased fibrosis of the myocardium, lung, and/or kidney; idiopathic pulmonary fibrosis (IPF); elevated left ventricular filling pressure (E/e′) indicative of diastolic dysfunction; and/or reduced cognitive function. In some embodiments, the methods include determining if the subject has mosaic loss of chromosome Y in blood (mLOY). Also provided are methods for preventing and/or treating diseases, disorders, and/or conditions associated with mLOY, which in some embodiments also include administering an anti-fibrotic therapy to the subject. Also provided are uses of inhibitors of TGFβ signaling or senolytic agents for prevention and/or treatment of diseases, disorders, and/or conditions associated with mLOY.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
In one aspect, the disclosure relates to micro-LED based AR displays combining stacked red, green, and blue LEDs, distributed Bragg reflectors, and diffractive optics; methods of making the same; and augmented reality displays using the same. In one aspect, the light generated by the LEDs is reflected within the optical cavity of DBR/LED/DBR, creating a highly directional (Δθ≤±5°) and monochromatic (FWHM≤5≤nm) blue light. In an aspect, the luminance of the disclosed inorganic-based micro-LEDs is orders of magnitude higher than that of organic LEDs while also providing high directionality and monochromaticity, leading to higher image quality. In a further aspect, the small size of the disclosed light source and combiner allows a much more compact and light-weight AR device to be constructed.
H10H 20/813 - Bodies having a plurality of light-emitting regions, e.g. multi-junction LEDs or light-emitting devices having photoluminescent regions within the bodies
H10H 20/825 - Materials of the light-emitting regions comprising only Group III-V materials, e.g. GaP containing nitrogen, e.g. GaN
12.
System, Method, and Computer Readable Medium for Capability-Enhanced Virtualization of Caches
An exemplary computing method of the present disclosure comprises processing a data request by translating a virtual memory address and a trust domain identifier associated with a thread being executed into a capability token that is associated with a physical capability register; determining that a cache line in cache memory of the computing device is allocated to the virtual memory address included in the data request; searching for and retrieving contents of the physical capability register that is associated with the capability token value; and granting access to the cache line in the cache memory if the contents of the physical capability register indicate that the cache line is one of the one or more cache line numbers that are allocated to the capability token associated with the thread being executed and the set of operations permit access to the cache line.
G06F 12/14 - Protection against unauthorised use of memory
G06F 12/0871 - Allocation or management of cache space
G06F 12/1045 - Address translation using associative or pseudo-associative address translation means, e.g. translation look-aside buffer [TLB] associated with a data cache
13.
Efficient High-Entropy Alloys Design Method Including Demonstration and Software
Embodiments relate to system and methods involving use of a technique for managing a database for producing a material composition having a thermodynamic phase. The technique can include: receiving a binary phase diagram for each material to be used as a component of a high-entropy alloy (HEA); using one or more active learning machine learning techniques for generating a feature, the feature including: a primary feature that is representative of a probability that an HEA will exhibit a solid solution phase and/or an intermetallic phase, and a physics-based feature that is representative of a factor related to formation of a desired intermetallic HEA phase; encoding the primary feature and the physics-based feature; generating an output representation of a HEA alloy composition and phase of a predicted materials composition; and selecting a HEA composition and phase that will meet a material design criterion.
Provided are compositions that include colchicine conjugated to behenic acid, optionally wherein the colchicine conjugated to behenic acid is encapsulated by a nanoliposome. In some embodiments, the colchicine is conjugated to behenic acid at the acetamide position of a B-ring of colchicine, the nanoliposome includes a lipid component comprising DSPC, DOPE, and DSPE-PEG, and cholesterol; and/or the colchicine conjugated to behenic acid is present in the nanoliposome in an amount of at least about 400, 500, 600, or more than 600 pg/mL. Also provided are methods for preparing behenic acid-conjugated colchicine derivatives, methods for preparing lipid nanoparticle-encapsulated colchicine derivatives, and methods for using the same to treat and/or prevent inflammatory and/or cardiovascular diseases, disorders, and/or conditions.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
15.
SUGAR-CONJUGATED LIPID NANOPARTICLES FOR TARGETED DELIVERY OF SIRNA TO HEPATOCYTES
Provided are compositions that include compositions of galactosyl-conjugated lipid, nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl-conjugated LNPs have a lipid component having D-Lin-MC3-DMA, ALC-0315 and SM-102, cholesterol, DSPC and DOPE, and DMG-2000-PEG. In some embodiments, the GaIN Ac-conjugated LNP has one or more galactosyl moieties bioconjugated to cholesterol present with a lipid component of the GaINAc-conjugated LNP. Also provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated with undesirable gene expression and methods for targeting active agents to hepatocytes using the presently disclosed GaIN Ac-conjugated LNPs.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
16.
ASSAY OPTIMIZATION CENTRIFUGAL MICROFLUIDIC DISC, METHODS OF USING, AND METHODS OF MAKING
The present disclosure provides for devices, systems, methods of using, and method of making an assay optimization centrifugal microfluidic device. The centrifugal microfluidic device includes a sample preparation domain. The sample preparation domain includes a first reagent chamber and a first distribution channel in fluidic communication with the first reagent chamber. The sample preparation device further includes a first network of metering channels furcating from the first distribution channel and a first plurality of valves, with individual valves in fluidic communication with individual metering channels. Additionally, the sample preparation domain includes a plurality of detection chambers with individual detection chambers connected to individual valves.
The present disclosure relates to compositions and methods related to tissue-specific promoters and their uses in plants, including tobacco and cannabis. The provided trichome-specific promoters enable the expression of heterologous polynucleotides in trichome tissues.
Methods of treating choroidal neovascularization in a patient in need thereof are described herein. In some aspects, the method comprises inhibiting telomerase activity within a biological compartment of the patient. In some instances, inhibiting telomerase activity comprises disposing a telomerase inhibitor and/or disposing an antisense oligonucleotide within the biological compartment of the patient. In some embodiments, the biological compartment of the patient is the eye. Further, in some instances, the patient has neovascular age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity (ROP), corneal neovascularization, and/or neovascular glaucoma.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61P 9/00 - Drugs for disorders of the cardiovascular system
An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg/dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg/dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 50/30 - Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
20.
SYSTEM AND METHOD FOR REAL-TIME PERSONALIZATION OF AUTOMATED INSULIN DELIVERY
An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg/dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg/dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A wind turbine platform, including a buoyancy tube disposed radially around a tower and/or stem for a floating wind turbine or around the tower and/or monopile for a fixed-bottom wind turbine, a plurality of buoyancy cables/spokes extending from the buoyancy tube to the stem and arranged to carry in tension an upward buoyancy force of the buoyancy tube, and a plurality of thrust cables/spokes extending from the buoyancy tube to the stem and/or tower and arranged along with the buoyancy cables to carry in tension a generally horizontal force imparted by at least one of rotor thrust, torque, wind, and wave forces.
Provided are methods for treating Alzheimer's Disease and/or ameliorating at least one symptom thereof. In some embodiments, the methods include administering to a. subject with AD an inhibitor of a clusterin biological activity, wherein the composition is administered via a route and in an amount sufficient to inhibit the clusterin biological activity to thereby treat the subject's. AD and/or ameliorate at least one symptom thereof. Also provided are methods for reducing and/or inhibiting myelin decay in a subject in need thereof and methods for inhibiting differentiation of oligodendrocyte progenitor cells (OPCs) to mature oligodendrocytes, the method comprising contacting the OPCs with a clusterin gene product or a functional fragment or derivative thereof.
L segment having a second amino acid sequence having amino acids 113-237 of SEQ ID NOs. 2 and 8-12, or both; nucleic acids encoding the same; methods for using the same to detect and/or target conformational states of FN in samples; methods for treating diseases and/or disorders and/or for meliorating at least one symptom of consequence of a disease or disorder associated with abnormal expression of a force-induced conformational state of FN in subjects; and methods for screening for compounds having selective binding activities for conformational states of FN.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C40B 20/04 - Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
In some examples, method for automatically computing a blood input function for dynamic positron emission tomography (PET) includes obtaining dynamic PET image data sets comprising volumetric radioactive measurement data associated with an administered radioactive tracer present in a target site of a subject over multiple scanning intervals. The method includes utilizing an artificial neural network (ANN) to segment the dynamic PET image data sets displaying one or more blood vessels in the target site. The method includes automatically deriving, using the ANN, a blood input function (I D I F) based on radioactive tracer concentrations measured in one or more segments of the plurality of dynamic PET image data sets. The method includes computing a predictive model-corrected blood input function (MCIF) using time activity curve input associated with the automatically derived IDIF.
Provided are composition that include stable TLR4 agonist (e.g., KDO2) containing nanoliposomes. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposome include a lipid component comprising, consisting essentially of, or consisting of DSPC, DOPE, PEG(2000)-PE, one or more TLR4 agonists (e.g., KDO2), Cholesterol, Rhodamine or DiD, and optionally DOTAP and/or DHP. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposomes are cationic, anionic, or neutral liposomes. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposome encapsulate one or more immunogenic peptides, which can be peptides associated with malignant melanoma, which optionally can be subsequences of tyrosinase, gplOO, MAGE-1,2,3,6, Melan-A/MART-1, and/or MAGE-3. Also provided are methods for treating and/or preventing malignant melanoma and for inducing anti-melanoma immune responses in subjects using the presently disclosed compositions.
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (USA)
UNIVERSITY OF MARYLAND, COLLEGE PARK (USA)
UNIVERSITY OF VIRGINIA PATENT FOUNDATION (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
UNIVERSITY OF SOUTH CAROLINA (USA)
Inventor
Hobart, Karl D.
Anderson, Travis J.
Tadjer, Marko J.
Jacobs, Alan G.
Graham, Samuel
Aller, Henry
Hopkins, Patrick
Goorsky, Mark
Khan, Asif
Feygelson, Tatyana I.
Pate, Bradford B.
Abstract
In one aspect, the disclosure relates to a device comprising a plurality of semiconductor layers; a phonon bridge layer formed on the plurality of semiconductor layers; a gate electrode set into the phonon bridge layer and in contact with a surface of the plurality of semiconductor layers; and a diamond layer formed over the phonon bridge layer. The phonon bridge layer can include materials that have a speed of sound in-between the speed of sound for the diamond layer and the speed of sound of the semiconductor layer that is in contact with the phonon bridge layer. In one aspect, the device is a transistor, such as a high electron mobility transistor. The disclosure, in another aspect, relates to methods of making the devices as disclosed herein.
H01L 21/28 - Manufacture of electrodes on semiconductor bodies using processes or apparatus not provided for in groups
H10D 62/83 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials being Group IV materials, e.g. B-doped Si or undoped Ge
H01L 21/768 - Applying interconnections to be used for carrying current between separate components within a device
H01L 23/373 - Cooling facilitated by selection of materials for the device
In one aspect, the disclosure relates to a process for acrylonitrile manufacture using forced dynamic operation over transition metal promoted bismuth molybdate-based catalysts. The forced dynamic operation leverages catalyst lattice oxygen in ammoxidation of propene to improved acrylonitrile productivity and yield. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
C07C 253/26 - Preparation of carboxylic acid nitriles by ammoxidation of hydrocarbons or substituted hydrocarbons containing carbon-to-carbon multiple bonds, e.g. unsaturated aldehydes
The present disclosure relates to compositions and methods related to modification of trichome density and transport of metabolite and their uses in plants, including tobacco and cannabis. The provided transcription factors enable the increase in trichome density in plants.
A universal heart port, in various embodiments, comprises: a cylindrical heart port body defining a circular top surface, an outer surface, and a cylindrical opening that extends through the heart port body; and one or more adapter coupling flanges, each respective adapter coupling flange of the one or more adapter coupling flanges extending radially outward along at least a portion of the top surface of the heart port body and comprising a respective end stop portion that extends perpendicularly downward from a respective end portion of the respective adapter coupling flange. In some embodiments, each of the adapter coupling flanges are substantially evenly spaced about the outer surface of the heart port body. In some embodiments, the heart port further comprises one or more adapters configured for selective coupling to the heart port. The adapters may include a plug, a canula adapter, an LVAD adapter, etc.
A61M 60/178 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart drawing blood from a ventricle and returning the blood to the arterial system via a cannula external to the ventricle, e.g. left or right ventricular assist devices
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (USA)
Inventor
Bart-Smith, Hilary
Loth, Eric
Zhu, Joseph Jianzhong
Moored, Keith W.
Mivehchi, Amin
Zuo, Lei
Bacelli, Giorgio
Keow, Alicia
Abstract
The present invention relates to a renewable energy system designed to harness hydrokinetic energy from riverine environments using bio-inspired hydrofoil mechanisms. The system comprises a pair of hydrofoils configured to oscillate out-of-phase in response to water flow, a mechanical motion rectifier to convert oscillatory motion into unidirectional rotary motion, and a generator to produce electrical energy. A support structure stabilizes the components, while a control system optimizes energy generation by adjusting hydrofoil pitch angles and oscillation parameters based on sensory feedback. This innovative approach offers a scalable, efficient, and environmentally friendly solution for riverine hydrokinetics, minimizing ecological impact and adapting to varying site conditions.
A differential extraction device includes a first fluidic layer, a second fluidic layer, and a valving layer disposed between the first and second fluidic layers and include multiple chambers and microfluidic channels. The valving layer provides the ability to selectively allow and prevent flow between various chambers. Reagent chambers deliver reagent to a sample chamber and multiple recovery chambers receive material from the sample chamber. The valving layer provides the ability to selectively allow and prevent flow between various chambers.
C08G 65/48 - Polymers modified by chemical after-treatment
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
A computer implemented method for controlling insulin dosing for a subject includes saving field collected glucose and insulin data for the subject. The method implements a virtual personal model, or digital twin, of the subject by using the field collected data to save electronic field collected traces of blood glucose levels and electronic field collected traces of insulin levels for the subject. A replay phase of the virtual personal model emulates test insulin therapies to generate virtual insulin doses that correspond to the field collected data. The method converges to a result by comparing field collected glucose traces and regenerated glucose traces. This method recommends a basal rate profile for the subject using saved replay data by calculating inversions of the virtual personal model by deconvolution.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.
Described herein are devices, systems, kits, and methods for, among other things, providing UV-C irradiation to central lines that are utilized to administer aqueous therapeutics that are delivered intravenously to a subject.
A flexible system for utilizing data from different monitoring techniques and capable of providing assistance to patients with diabetes at several scalable levels, ranging from advice about long-term trends and prognosis to real-time automated closed-loop control (artificial pancreas). These scalable monitoring and treatment strategies are delivered by a unified system called the Diabetes Assistant (DiAs) platform. The system provides a foundation for implementation of various monitoring, advisory, and automated diabetes treatment algorithms or methods. The DiAs recommendations are tailored to the specifics of an individual patient, and to the patient risk assessment at any given moment.
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
39.
NAD(H) NANOPARTICLES AND METHODS OF REDUCING VEIN GRAFT INJURY AND IMPROVING VEIN GRAFT HEALTH
The present technology provides methods of reducing vein graft injury comprising administering an effective amount of a bioavailable nanoparticle comprising NAD+ and/or NADH to the vein to be grafted prior to surgical implantation of the vein graft in a subject. Additionally, the present technology provides methods of improving vein graft health and preventing or treating post-operative restenosis and also provides bioavailable nanoparticles comprising NAD+ and/or NADH and a coating comprising a human cell membrane for use in such methods.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C04B 28/18 - Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing mixtures of the silica-lime type
Disclosed are compositions and methods for treating a disease or disorder such as cancer in a subject in need thereof. In some embodiments, the methods include administering to the subject a vector that has a first nucleic acid sequence encoding a promoter operably linked to each of a second nucleic acid sequence encoding a therapeutic polypeptide, and a third nucleic acid sequence encoding a peptide domain that is stabilized when phosphorylated by kinase activity in a target cell and/or tissue. In some embodiments, the target cell and/or tissue can be a cell and/or tissue undergoing a stress response. In some embodiments, the target cell and/or tissue can be a cell and/or tissue in which a CK2 kinase is active. The kinase activity can be elevated extracellular regulated kinase (ERK) activity, p38 MAP kinase activity, and/or CK2 activity.
To address most recurrent pathogenic mutations associated with SCN8A-related epileptic encephalopathy, disclosed herein are SCN8A-targeting adenine or cytosine base editors designed to correct the following clinically relevant SCN8A gene variants: R1872W, R1872Q, R1617Q, R850Q, N1877S, and G1475R. By targeting these six recurrent genetic mutations, a personalized gene therapy solution for this type of pediatric epilepsy is provided.
Inline classification of a biological specimen including mammalian cells can include generating an alternating current (AC) electrical stimulus to an electrode structure. The electrode structure can be electrically coupled with a flow cell. A response, elicited by the electrical stimulus, can be received when a model specimen class traverses the flow cell. Using the received response, a corresponding impedance parameter value can be determined, the value indicative of a specified biophysical characteristic corresponding to the model specimen class. The first impedance parameter can be translated to a value corresponding to the specified biophysical characteristic.
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
This application generally relates to stable peptide compositions and kits comprising low levels of buffering and chelating agents, and methods of using the same.
Provided are compositions that include single cell suspensions of pancreatic islet cells, pancreatic islet-like cells derived from iPS cells, or combinations thereof, wherein the cells are present within a MAP scaffold and/or are encapsulated by MAPs. In some embodiments, the MAP scaffold and/the MAPs have a polymer backbone that includes poly(ethyleneglycol) (PEG), hyaluronic acid, polyacrylamide, polymethacrylate, alginate, collagen, or any combination thereof. Also provided are methods for using the presently disclosed compositions for treating Type 1 diabetes, for example by administering to a subject with Type 1 diabetes such a composition via a route and in an amount effective for treating the Type 1 diabetes in the subject. In some embodiments, the administering includes injecting the composition into a kidney capsule, subcutaneously, intraperitoneally, into adipose tissue, intramuscularly, intrahepatically, and/or intrapancreatically into the subject.
A computer implemented method of reconstructing magnetic resonance images (MRI) in Cartesian coordinates uses acquired magnetic resonance data and implements a Fourier transform to place the MRI data in k-space. The method allows for under-sampling the k-space and achieving an accurate output image by selecting an image model to map the sampled data and iteratively converge the model to an output that matches a region of interest subject to the MRI. The image model may be an alternating direction method of multipliers (ADMM) or an ADMM with non-convex low rank regularization algorithm. A de-noising algorithm may be at least one of a plug and play block matching and 3D filtering (PnP-BM3D), a plug and play weighted nuclear norm minimization (WNNM), or a plug and play denoising convolutional neural networks (PnP-DnCNN) algorithm. An iterative optimization of the variables of the model yields an output image.
Boronated prodrugs have been developed that are particularly advantageous for use in boron proton capture therapy (BPCT) and boron neutron capture therapy (BNCT). Cancer-targeting moieties, such as heptamethine cyanine dyes (HMCDs), are linked to compounds including a plurality of boron isotopes, e.g., carboranes such as 1-amino-1-carbadodecaborate. Compounds of the present disclosure were demonstrated to deliver eleven boron-11 atoms per dye molecule selectively to breast cancer cells. Upon irradiation with proton or neutron beams and subsequent nuclear fusion reaction by proton capture, unstable 12C is generated in place of 11B, which is short lived and releases high energy alpha particles. There particles travel only a short distance within cell and/or a very close tumor microenvironment, damaging cellular DNA ultimately resulting in killing cancer cells, and are particularly useful with young patients and with deep tissue tumors located in critical organs which are difficult to remove by surgery.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Various processes, algorithms, and systems are provided herein for assisting physicians in distinguishing among related diseases, such as distinguishing connective tissue associated interstitial lung disease from idiopathic pulmonary fibrosis. Methods for generating such processes, algorithms, and systems are also disclosed. In some embodiments, a preliminary diagnosis of a set of possible diseases is obtained, along with protein count information from a patient's blood sample. Additional, patient-specific information (e.g., age, sex, etc.) may also be obtained. The data is processed by a trained machine learning algorithm, to output a differential diagnosis of which of the set of possible diseases is present for that patient. Based on the diagnosis, a treatment course can be selected, and further information can be tracked regarding the patient's outcome.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/08 - Measuring devices for evaluating the respiratory organs
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
According to various aspects, an electrochemical storage device includes an electrode. The electrode includes TiNb2O7, LiCoO2, LiNi0.5Mn0.5O2, lithium metal, LiMn2O4, Li4Ti5O12, a mixture of LiMn2O4 and LiCoO2, or mixture thereof.
H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
50.
SYSTEM, METHOD, AND COMPUTER READABLE MEDIUM FOR DIAGNOSING AN INDIVIDUAL'S PERSONAL SALT INDEX
Described herein are systems, methods, and computer readable medium for, among other things, determining an individual's personal salt index. Such systems, methods, and computer readable medium can be utilized for providing information that can help guide healthcare providers by making informed decisions about treatments based on the individuals salt index. Such informed decisions can help mitigate the worsening or possibility of an adverse cardiovascular event in an individual whose salt index is unknown and receiving a treatment modality that may not be suitable for their particular genotype, phenotype, or any combination thereof. An aspect of the present disclosure also provides a system, method and computer readable medium for, among other things, algorithms/models that enabled the determination of a individual salt index to enable the therapeutic intervention. Also described herein are compositions, pharmaceutical compositions, kits, and methods of administration relating to therapeutics for blood pressure normalization and/or pathological cardiovascular diseases/phenotypes.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
51.
METHOD AND SYSTEM FOR ALL-AQUEOUS PRINTING OF VISCOELASTIC DROPLETS
This document describes printing viscoelastic material in an aqueous medium. Such printing can involve positioning a print nozzle at specified coordinates in the medium and triggering deposition of the viscoelastic material to form a viscoelastic droplet. The deposition can be established by delivering a specified flow velocity of the viscoelastic material through an aperture in the print nozzle. The print nozzle can be detached from the droplet and a receiving material by translating the nozzle relative to the droplet according to a specified acceleration. The droplet can remain captive on or within the receiving material upon detachment from the nozzle.
B29C 64/112 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using individual droplets, e.g. from jetting heads
Disclosed is a method of treating lung injury in a patient comprising providing a therapeutically effective amount of a pharmaceutical agent that enhances peroxisome biogenesis to a patient. The method includes increasing the number of peroxisomes in alveolar macrophages, decreasing peroxisome degradation, and improving peroxisome function in alveolar macrophages. Increasing the number and function of peroxisomes in alveolar macrophages promotes healing of lung injury and regeneration of alveolar epithelial. The lung injury may be due to infection, including viral infection, such as SARS-CoV-2 infection or influenza infection. The lung injury may also be due to exposure to caustic substances, tobacco smoke, asbestos, or fine particulate matter.
The present disclosure provides for compounds including derivatives of haloperidol, pharmaceutical compositions including haloperidol derivatives, methods of use of the haloperidol derivatives and their pharmaceutical compositions, and the like. Compounds and pharmaceutical compositions of the present disclosure can be used in combination with one or more therapeutic agents for treating inflammatory arthritis, gout, or other inflammation-related diseases or conditions.
An insulin delivery supervisor (IDS) with a safety analysis and supervision function that can reside between the insulin request and the insulin delivery and can intercept any excessive insulin requests before the insulin was delivered. The IDS can be implemented in any system based on insulin pump or pen and will work with either SMBG or CGM modes of blood glucose monitoring.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
55.
SYSTEMS AND METHODS OF PROCESSING BRINE TO CAPTURE LITHIUM IONS
The present disclosure provides for methods and systems for processing brine to obtain lithium. The present disclosure provides for methods that leverages intercalation materials and drives lithium capture using a chemical approach to treating brine as opposed an electrochemical approach, which can be complicated and expensive. The present disclosure provides for a chemical redox-driven approach to selectively extract Li+ from brine.
ii = 82 nM, 122-fold SphK2 selective) with validated in vivo activity. Modifications to the guanidine head of the inhibitor provided compounds that were effective in alleviating the observed poor oral bioavailability.
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
Provided are methods for treating viral infections in subject in need thereof. In some embodiments, the method include administering to the subject a composition that has an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike. Also provided are compositions that include an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike, which compositions can optionally be employed in the disclosed methods.
Provided are methods and compositions for treating and/or preventing C. difficile infections, particularly recurring C. difficile infections. The compositions for use in treating and/or preventing C. difficile infections include in some embodiments at least one agent that inhibits an alpha 2 adrenergic receptor, and the presently disclosed methods include administering at least one such composition to a subject in need thereof, optionally in combination with other therapeutically active agents including but not limited to an enhancer of an IL-13 biological activity, optionally an IL-13 peptide or a fragment or homolog thereof; an interleukin-13 receptor subunit alpha-2 (IL-13Ra2) inhibitor; an enhancer of an Interleukin-33 (IL-33) biological activity, optionally an IL-33 polypeptide or a biologically active fragment or homolog thereof; or any combination thereof.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
Compositions and methods for regenerating pancreatic islet viability and/or cell proliferation in vitro, ex vivo, and/or in vivo; and/or for regenerating glucose-stimulated insulin secretion; and/or for regenerating viability and/or cell proliferation of a transplanted pancreatic islets; and/or for preventing and/or inhibiting rejection of a transplanted islets; and/or for pancreatic islet transplantation; and/or for treating a symptom of a condition, disorder, or disease associated with abnormal insulin responsiveness to glucose are provided. In some embodiments, the compositions include a peptide and/or a pharmaceutically acceptable salt thereof, and/or a biologically active fragment, analog, or derivative thereof, wherein the peptide, the pharmaceutically acceptable salt thereof, and/or the biologically active fragment, analog, or derivative thereof has an amino acid sequence of any of SEQ ID NOs: 1-60, or any combination thereof.
Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods include administration of combinations of agents, including combinations that include dupilumab. The methods can be used to treat subjects diagnosed with a SARS-CoV-2 infection, including those already hospitalized to treat COVID-19 and/or those also having lymphopenia, to reduce the severity of outcomes related to COVID-19, such as admittance to the intensive care unit (ICU), mechanical ventilation, and/or death, particularly over periods of time longer than a month or two months following the initial administration of the agents. Compositions for use in the treatment of COVID-19 are also described.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Various technological aspects of functional tremor retrainment are described. For example, a mobile device may measure a baseline tremor frequency, determine a cue frequency based on the baseline tremor frequency, provide motion cues at the cue frequency, measure a motion frequency while providing the motion cues, and provide a feedback signal indicative of a synchrony of the motion frequency to the cue frequency.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A63B 24/00 - Electric or electronic controls for exercising apparatus of groups
A63B 71/06 - Indicating or scoring devices for games or players
62.
METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
63.
METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
64.
BIFUNCTIONAL IL-2 AND IL-33 PROTEINS FOR TREATING AUTOIMMUNE DISEASE
The present invention provides, among other things, compositions and methods for prophylaxis and treatment of autoimmune disease. The present invention provides, in part, bifunctional proteins comprising interleukin-2 (IL-2) and interleukin-33 (IL-33) variants having increased manufacturability and activity, which synergistically expand or stimulate tissue targeting or reparative regulatory T cells. The present invention provides compositions and methods for proliferation and activity of ST24+ regulatory T cells.
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
65.
METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
The present invention provides, among other tilings, improved interleukin-33 (IL-33) variants engineered for increased manufacturability and activity, for example, mutated at one or more of N60, C116, C97, C121 or C148 relative to a truncated IL-33. The present invention also provides a. multifunctional fusion protein comprising an IL-33 variant associated with an IL-2 polypeptide and optionally, a half-life extension moiety. The present invention further provides compositions and methods for proliferation and activity of ST2+ regulatory T cells, for prophylaxis and treatment of autoimmune disease.
The present invention provides, among other things, compositions and methods for prophylaxis and treatment of cancer and other diseases. The present invention provides, in part, a bifunctional protein comprising an IL-2 variant biased to IL-2Rβ, and an interleukin- 33 (IL-33) variant engineered for increased activity and/or manufacturability. The present invention, for example, provides IL-2 variants mutated at one or more of F42, L80, R81, L85, 186 or 192 relative to wild-type IL-2 associated with IL-33 variants mutated at one or more of N60, Cl 16, C97, C121 or CMS relative to a truncated IL-33, that preferentially expands T effector cells. The present invention, among other things, provides a bifunctional fusion protein, optionally linking an IL-2 variant biased to IL-2Rβ, and an interleukin-33 (IL-33) variant via a linker, that preferentially expands T effector cells.
Apparatus and techniques described herein can include or use a rotationally-driven microfluidic assembly. For example, a sample can be propelled to a sample recovery chamber from a sample chamber using a gas evolved from a reaction between the liquid reagent and a dry reagent. Such gas evolution can provide displacement of a sample liquid or other liquid in an inward direction, such as proximally toward a center of rotation. Such gas evolution can include features or reagents, or both, that are compatible with downstream nucleic acid amplification tests.
Iowa State University Research Foundation, Inc. (USA)
Inventor
Zhang, Sen
Yin, Zhouyang
Qi, Long
Huang, Wenyu
Yu, Jiaqi
Abstract
The present disclosure provides for hybrid catalysts, methods of converting CO2 to C2 products (e.g., ethylene), systems for converting CO2 to C2 products (e.g., ethylene), and the like. The hybrid catalyst of the present disclosure effectively uses two steps of converting CO2 to ethylene in a single hybrid catalyst.
C07C 1/12 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon dioxide with hydrogen
A method can include receiving a biological sample including the target cells, e.g., at an inlet of a microfluidic structure. This can involve flowing the target cells, e.g., suspended in a first buffer, at a first flow rate within a main channel of the microfluidic structure. At least one focusing flow can be applied to the biological sample, using a second buffer at a second flow rate, to help establish a boundary defining a central region or streamline. The central region can contain the target cells within the main channel and promote ion diffusion between the first and second buffers.
SLC2A11-MIFSLC2A11-MIF was identified that is present in nearly 50% of CRC samples but absent in non-cancer colon tissue. Disclosed herein is a method for diagnosing and treating cancers expressing this chimeric RNA and protein.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
Provided are a method, system, and computer-readable medium for personalizing titration measurement for basal insulin dosing. The personalization can be achieved using spare self-monitoring blood glucose (SMBG) and/or dense continuous glucose monitoring (CGM) data to predict a fasting blood glucose (FBG) envelope accounting for online estimation of titration noise representative of variability in daily fasting measurement. As a result, basal insulin dosing directed to causing the FBG envelope to be maintained for an optimal glycemic range can then be obtained.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
G01N 33/66 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood sugars, e.g. galactose
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
75.
ELECTROPHILIC PURINE COMPOUNDS FOR MODIFICATION OF PROTEINS
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventor
Hsu, Ku-Lung
Li, Zhihong
Abstract
Electrophilic purine-based compounds comprising mono- and di-halo-substituted purine moieties are described. The compounds also include acetamide substituents. The compounds are reactive in nucleophilic aromatic substitution reactions. The compounds generally showed the highest reactivity when a thiol was used as the nucleophile. Methods of using the compounds to covalently modify proteins containing nucleophilic side chains and/or to modulate protein activity are also described.
C07D 473/40 - Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Provided are compositions that include compositions of galactosyl -conjugated lipid nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl- conjugated LNPs have a lipid component having D-Lin~MC3-DMA, ALC-0315 and. SM-102, cholesterol, DSPC and DOPE, and DMG-2000-PEG. In some embodiments, the GalNAc-conjugated LNP has one or more galactosyl moieties bioconjugated to cholesterol present with a lipid component of the GalNAc -conjugated LNP. Also provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated, with undesirable PCSK9 gene expression, optionally a cardiovascular disease, disorder, or condition, including but not limited, to atherosclerosis and/or thrombosis, and sepsis, septic shock, cytokine storm, or sequelae thereof.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
77.
SYSTEMS AND METHODS FOR OPTIMIZATION OF RADIATION TREATMENT PLANNING TO IMPROVE IMMUNE RESPONSE
Systems and methods are provided for estimating immune response effected by patient specific and plan specific radiation treatments (such as, e.g., SBRT). The systems and methods may take into account radiation impact on circulating immune blood cell types or sub-types, such as T lymphocytes, B lymphocytes, natural killer cells, erythrocytes, and/or neutrophils, and predict time dependent fractional blood count and cell kill following radiation therapy treatment. Additionally, the system, method, and computer readable medium provide parameters such as a dose dependent lymphocyte kill function and average net release rate of new lymphocytes into circulating blood (including promotion of cytotoxic T cells and suppression of lymphocytes in blood), which may be used for optimization of RT treatment plans.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
Various aspects of the instant disclosure provide a metal-organic framework- polymer composite organic-gel material. The material includes zirconium -based MOF (UiO-66) and multiple polymer components to form a gel network and exhibit multifunctionality (conductivity and piezoelectricity).
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07F 7/00 - Compounds containing elements of Groups 4 or 14 of the Periodic Table
C08G 83/00 - Macromolecular compounds not provided for in groups
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
79.
ELECTRODES, BATTERIES INCLUDING THE ELECTRODES, AND METHODS OF MAKING BATTERIES
The present disclosure provides for electrodes, batteries that include the electrodes, method of making electrodes and the like. The present disclosure provides for electrodes that are thicker than typical electrodes that have a higher energy density at the cell level, regardless of the specific cell chemistry. The electrodes are all active material (AAM) electrodes (e.g., AAM anodes and AAM cathodes). In an aspect, the electrodes of the present disclosure have improved ion transport in the electrode microstructure and the concomitant reduced tortuosity and improved retention of electrochemical capacity at increased cycling rates.
H01M 10/056 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes
H01G 11/24 - Electrodes characterised by structural features of the materials making up or comprised in the electrodes, e.g. form, surface area or porosityElectrodes characterised by the structural features of powders or particles used therefor
H01G 11/60 - Liquid electrolytes characterised by the solvent
H01G 11/62 - Liquid electrolytes characterised by the solute, e.g. salts, anions or cations therein
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
80.
SYSTEMS AND METHODS RELATED TO COMPETITION AND MUTUALISM IN THE DYSBIOTIC VAGINAL MICROBIOME
Described herein are systems, methods, and computer readable medium for, among other things, predictive platforms for novel microbial therapeutics. Such systems, methods, and computer readable medium can be utilized for identifying candidate therapeutics and/microbiota for administration against a candidate bacterial infection in particular. In embodiment, the bacterial infection is bacterial vaginosis. An aspect of the present disclosure also provides a system, method and computer readable medium for, among other things, algorithms/models that enabled the predictions of the specific combinations of bacteria and putative therapeutic targets to enable the therapeutic intervention.
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
Provided are biomarkers for parenteral nutrition associated cholestasis (PNAC) in subjects, especially infants receiving parenteral nutrition (PN). Using such biomarkers provide methods of diagnosing and/or assessing risk of PNAC in a subject, including screening a sample from a subject believed to be at risk for PNAC for one or more biomarkers of PNAC. The biomarkers can include one or more fecal metabolites. Such biomarkers and associated methods provide neonatal intensive care unit clinicians with an additional tool for early identification of PNAC risk. Early identification of high-risk infants would enable clinicians to confidently optimize caloric nutrition with PN for infants at low risk of developing PNAC and enable proactive mitigation with alterations to the administered PN.
In one aspect, the disclosure relates to an apparatus comprising: a plate; a plurality of wells set into the plate, wherein each individual well of the plurality of wells extends from an outer surface of the plate to an inner surface of the individual well; and a plurality of hydrogels, wherein at least two individual wells of the plurality of wells each comprise a singular hydrogel of the plurality of hydrogels; wherein each individual hydrogel of the plurality of hydrogels comprises a dithiol crosslinker and a first backbone polymer functionalized with an alkene; and wherein at least one hydrogel of the plurality of hydrogels is different from the remaining hydrogels of the plurality of hydrogels. Also disclosed herein are methods of fabricating the apparatus. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the disclosure.
Disclosed are various approaches for bit-serial computing embedded in the DRAM subarray, leveraging the massive parallelism of DRAM row operations. The present disclosure discloses digital techniques that can outperform analog charge-sharing techniques. Digital techniques can use more area but support a wider range of computing primitives, and allow a sequence of logic operations to be performed at higher clock speeds, be-tween slower subarray row reads/writes. The present disclosure describes a range of bit-serial architectures, and evaluate raw performance as well as area and energy efficiency. Results show that the digital architecture demonstrates 20× speedup over CPU, 5× over GPU, and 1.7× over SIMDRAM, an analog architecture.
Systems and methods of generating music that encodes personalized information implement and/or include generating a personalized sonification model based on music modeling data pertaining to a user; receiving physiological data pertaining to the user, wherein the physiological data is related to at least one of a physical wellness or a behavioral wellness of the user; generating a melody, wherein the melody encodes a wellness information or modification based on the personalized sonification model and the physiological data; and providing the melody to the user to convey the wellness information or modification.
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
The capillary transfer technology presented here represents a powerful approach to transfer soft films from surface of liquid onto a solid substrate in a fast and defect-free manner. The fundamental theoretical model and transfer criteria validated with comprehensive experiments and finite element analyses, for the first time provides a quantitative guide and optimization for the choice of material systems, operating conditions and environments for scalable on-demand transfers with high yield. The intrinsically moderate capillary transfer force and externally selectable transfer direction offer robust capabilities for achieving deterministic assembly and surface properties of structures with complex layouts and patterns for potentially broad applications in the fabrication of flexible/stretchable electronics, surface wetting structures and optical devices. Integration of this technology with other advanced manufacturing technologies associated with material self-assembly, growth and layout alignment represents promising future topics and would help create emerging new manufacturing technologies that leverage unique fluidity of liquid environments.
H05K 3/20 - Apparatus or processes for manufacturing printed circuits in which conductive material is applied to the insulating support in such a manner as to form the desired conductive pattern by affixing prefabricated conductor pattern
Provided are embodiments of a device, having a device body suitable to hold a syringe. The device body can have an elongated member with a distal support and a proximal support. The device further includes a ratcheting rod configured to fit moveably within an open chamber in the elongated member, where the ratcheting rod has a proximal end configured to connect to a plunger of the syringe. The device can include a lever handle hingedly connected to a distal end of the device body, and a ratcheting lever hingedly connected to a distal end of the lever handle and positioned to interact with the ratcheting rod. Compression of the lever handle forces the ratcheting lever to extend the ratcheting rod in a proximal direction and to extract the plunger of the syringe.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
88.
FERROELECTRIC MIXED METAL OXIDE FILMS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME
(1-x)x(2-y)(2-y) (1) where M is zirconium, cerium, aluminum, silicon, lanthanum, yttrium, strontium, gadolinum, strontium, gallium, calcium, magnesium, or a combination thereof; where x is 0.05 to 0.95 and where the mixed metal oxide film is formed in the presence of a plasma; where the plasma is formed in an atmosphere that comprises nitrogen and oxygen in a molar ratio of 0.5:1 to 10:1; and where y is 0 to 0.5.
The present disclosure provides for graphene hybrid materials, methods of making graphene hybrid materials, batteries, methods of making batteries, methods of using batteries, shielding including the graphene hybrid materials, and the like. In an aspect, the graphene hybrid material is a carbon nanotube/graphene hybrid material, where the carbon nanotubes are grown on the surface of the graphene.
dd(t)). The processor can determine a glucose rate of change (G'(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G'(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.
G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
G05B 13/04 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric involving the use of models or simulators
91.
CARD9 ATTENUATES AB PATHOLOGY AND MODIFIES MICROGLIAL RESPONSES IN AN ALZHEIMER’S DISEASE
Provided herein are methods and compositions to enhance or activate protective microglial activities (such as phagocytosis of neurotoxic material) by activating CARD9.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
92.
METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
93.
DOUBLE-NETWORK HYDROGEL PARTICLES, METHODS OF MAKING DOUBLE-NETWORK HYDROGEL PARTICLES, AND METHODS OF MAKING OBJECTS
The present disclosure provides for double-network hydrogel particles, methods of making double-network hydrogel particles, methods of making objects (e.g., three-dimensional objects) using double-network hydrogel particle, and the like. In an aspect, double-network hydrogel particles are viscoelastic voxels (e.g., spherical or semi-spherical) that can be precisely manipulated in three-dimensional space and can be used in both soft matter science and biomanufacturing. The present disclosure provides for a voxelated bioprinting technology that enables the digital assembly of interpenetrating double-network hydrogel particles to form objects, in particular three-dimensional objects.
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
Disclosed herein is a biosensor fusion protein comprising an N-terminal half of a human liver fatty acid binding protein (hLFABP) and a C-terminal half of the hLFABP separated by a circularly permuted fluorescent protein (cpFP), wherein the binding of the N-terminal half of the hLFABP and the C-terminal half of the of the hLFABP to a per- or polyfluoroalkyl substance (PFAS) elicits a change in fluorescence of the cpFP. Also disclosed method for detecting per- and polyfluoroalkyl substances (PFAS) in a sample, comprising contacting the sample with the biosensor disclosed herein, assaying the sample for fluorescence, wherein an increase in fluorescence is an indication of the presence of PFAS. In some embodiments, the PFAS is perfluorooctanoic acid (PFOA). In some embodiments, the sample is a water sample.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
The present disclosure presents systems and methods for implementing a quantum error correction code with quantum light. One such method comprises iteratively training, by a computing system using reinforcement learning, at least one neural network that is interacting with a model of a measurement-based quantum optical circuit to generate circuit parameters for the measurement-based quantum optical circuit, wherein the generated circuit parameters produce a target optical quantum state of the measurement-based quantum optical circuit; applying the generated circuit parameters to the measurement-based quantum optical circuit; and/or outputting a quantum state of the measurement-based quantum optical circuit.
G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation
H03M 13/00 - Coding, decoding or code conversion, for error detection or error correctionCoding theory basic assumptionsCoding boundsError probability evaluation methodsChannel modelsSimulation or testing of codes
G06F 11/08 - Error detection or correction by redundancy in data representation, e.g. by using checking codes
Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G′(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G′(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
97.
REPRESSED ANG 1-7 IN COVID-19 IS INVERSELY ASSOCIATED WITH INFLAMMATION AND COAGULATION
Provided are methods for treating subjects with coronavirus infections. The methods include providing a subject infected with a coronavirus resulting in a prothrombotic condition in addition to being infected by a coronavirus, and administering to the subject an angiotensin (1-7) peptide or an analog or derivative thereof, a Mas Receptor (MasR) agonist, or any combination thereof. The subject may be suffering from COVID-19 disease, including but not limited to a thrombotic complication, an adverse pregnancy outcome, and/or a complication resulting from an underlying prothrombotic state. Also provided are compositions that include Ang (1-7) peptides, analogs, and/or derivatives thereof that are associated with degradable and/or non-degradable polymers having electrostatic interactions therewith, hydrophobic interaction therewith, hydrogen bonding interactions therewith, or any combination thereof. Also provided are uses of Ang (1-7) peptides, analogs, and/or derivatives thereof and/or a Mas Receptor (MasR) agonists for treating subjects infected with coronaviruses and/or for preparing medicaments therefore.
The present application discloses a novel fusion peptide of IL-2 and IL-33 and its use. It comprises a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment or homolog thereof, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment or homolog thereof. The two portions can be linked by a linker sequence. The application discloses that combination therapies using IL-2 and IL-33 or a therapy using the IL233 fusion protein are effective in preventing or treating diseases and disorders such as autoimmune diseases and disorders, inflammation, etc. Depending on the subject's disease or disorder, the compositions of the invention are useful for preventing certain symptoms, treating the disease, and alleviating at least some of the symptoms.
The present disclosure presents systems and related methods of programming with concepts. One such method comprises implementing, by a computing device, at least one concept of an application as a full-stack concept codebase, wherein syntax and semantics of the concept codebase are generated using an available programming language; organizing, by the computing device, concept codebases into one or more codebase directories; and/or composing, by the computing device, a plurality of concept codebases from the one or more codebase directories into a larger concept codebase using composition operators to build a complete concept-based full-stack application system.
Embodiments relate to a system for processing glucose data by efficient glucose database management. The system includes a physical data store containing glucose measurement data and a representation for at least one cluster of the glucose measurement data, wherein the representation approximates a glycemic profile vector array for a cluster of multiple glucose profiles segmented by plural time ranges. The system includes a processor and computer memory configured with instructions stored thereon that when executed will cause the processor to: 1) receive glucose measurements; 2) convert the glucose measurements into vectorial form; 3) search the physical data store by comparing a newly received glucose measurement to a centroid of a cluster using a similarity metric; 3) classify the newly received glucose measurement with a cluster having a matched similarity metric based on the comparing; and 4) ascribe a treatment to the newly received glucose measurement.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
